Tavapadon met the primary endpoint in the pivotal Phase 3, TEMPO-1 fixed-dose monotherapy trial, demonstrating a statistically significant improvement from baseline in the MDS-UPDRS Parts II and III ...
Aggregated α-synuclein plays an important role in the pathogenesis of Parkinson’s disease. The monoclonal antibody prasinezumab, directed at aggregated α-synuclein, is being studied for its effect on ...
Buntanetap showed dose-dependent and statistically significant improvements in cognition in the overall enrolled PD population. Parkinson’s patients with substantial cognitive decline exhibited a very ...
Roche and Prothena today announced topline results from the first half of their Phase 2 trial of the α-synuclein antibody prasinezumab. Results were negative on the MDS-UPDRS, the primary outcome ...
SAN DIEGO -- Both fixed and flexible doses of investigational tavapadon met their primary endpoint in phase III trials of early Parkinson's disease. In the TEMPO-1 (fixed dose) and TEMPO-2 (flexible ...
A recent study published in the New England Journal of Medicine conducted a trial of lixisenatide to assess its effects in early Parkinson’s disease. Study: Trial of Lixisenatide in Early Parkinson’s ...
SAN DIEGO — Tavapadon, a novel and highly selective partial agonist of dopamine D1 and D5 receptors, significantly improved motor function without increasing impulse control disorders in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback